These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 30663278

  • 1. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort.
    Mondi A, Cozzi-Lepri A, Tavelli A, Rusconi S, Vichi F, Ceccherini-Silberstein F, Calcagno A, De Luca A, Maggiolo F, Marchetti G, Antinori A, d'Arminio Monforte A, Icona Foundation Study Group.
    J Int AIDS Soc; 2019 Jan; 22(1):e25227. PubMed ID: 30663278
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.
    Rodriguez-Gonzalez CG, Chamorro-de-Vega E, Ortega-Navarro C, Alonso R, Herranz-Alonso A, Sanjurjo-Saez M.
    Ann Pharmacother; 2020 Jul; 54(7):633-643. PubMed ID: 31910643
    [Abstract] [Full Text] [Related]

  • 3. Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort.
    Ciccullo A, Baldin G, Borghi V, Lagi F, Latini A, d'Ettorre G, Oreni L, Fusco P, Capetti A, Fabbiani M, Giacomelli A, Grimaldi A, Madeddu G, Sterrantino G, Mussini C, Di Giambenedetto S.
    Viruses; 2022 Jan 17; 14(1):. PubMed ID: 35062367
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study.
    D'arminio Monforte A, Tavelli A, Sala M, Mondi A, Rusconi S, Antinori S, Puoti M, Celesia BM, Taramasso L, Saracino A, Antinori A, Cozzi-Lepri A, ICONA Foundation Study Group.
    J Antimicrob Chemother; 2023 Apr 03; 78(4):933-945. PubMed ID: 36775983
    [Abstract] [Full Text] [Related]

  • 7. Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE).
    Ciccullo A, Baldin G, Capetti A, Borghi V, Sterrantino G, Latini A, Madeddu G, Celani L, Vignale F, Rossetti B, Dusina A, Cossu MV, Restelli S, Gennari W, Lagi F, Giacomelli A, Colafigli M, Brescini L, Borghetti A, Mussini C, Rusconi S, Di Giambenedetto S.
    BMJ Open; 2019 Dec 02; 9(12):e029960. PubMed ID: 31796476
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single-tablet regimen in a multicentre cohort in Spain.
    Suárez-García I, Alejos B, Ruiz-Algueró M, García Yubero C, Moreno C, Bernal E, Pérez-Is L, Zubero Z, de Zárraga Fernández MA, Samperiz Abad G, Jarrín I, Cohort of the Spanish HIV/AIDS Research Network (CoRIS).
    J Int AIDS Soc; 2021 Jul 02; 24(7):e25758. PubMed ID: 34291580
    [Abstract] [Full Text] [Related]

  • 9. Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study.
    Taramasso L, De Vito A, Ricci ED, Orofino G, Squillace N, Menzaghi B, Molteni C, Gulminetti R, De Socio GV, Pellicanò GF, Sarchi E, Celesia BM, Calza L, Rusconi S, Valsecchi L, Martinelli CV, Cascio A, Maggi P, Vichi F, Angioni G, Guadagnino G, Cenderello G, Dentone C, Bandera A, Falasca K, Bonfanti P, Di Biagio A, Madeddu G, Behalf of the CISAI Study Group.
    AIDS Patient Care STDS; 2021 Sep 02; 35(9):342-353. PubMed ID: 34524918
    [Abstract] [Full Text] [Related]

  • 10. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
    Gagliardini R, Gianotti N, Maggiolo F, Cozzi-Lepri A, Antinori A, Nozza S, Lapadula G, De Luca A, Mussini C, Gori A, Saracino A, Andreoni M, Monforte AD, ICONA Foundation Study Group.
    Int J Antimicrob Agents; 2021 Oct 02; 58(4):106406. PubMed ID: 34293454
    [Abstract] [Full Text] [Related]

  • 11. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Molina JM, Ward D, Brar I, Mills A, Stellbrink HJ, López-Cortés L, Ruane P, Podzamczer D, Brinson C, Custodio J, Liu H, Andreatta K, Martin H, Cheng A, Quirk E.
    Lancet HIV; 2018 Jul 02; 5(7):e357-e365. PubMed ID: 29925489
    [Abstract] [Full Text] [Related]

  • 12. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
    Hidalgo-Tenorio C, Cortés LL, Gutiérrez A, Santos J, Omar M, Gálvez C, Sequera S, Jesús SE, Téllez F, Fernández E, García C, Pasquau J.
    Medicine (Baltimore); 2019 Aug 02; 98(32):e16813. PubMed ID: 31393412
    [Abstract] [Full Text] [Related]

  • 13. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
    Trottier B, Lake JE, Logue K, Brinson C, Santiago L, Brennan C, Koteff JA, Wynne B, Hopking J, Granier C, Aboud M.
    Antivir Ther; 2017 Aug 02; 22(4):295-305. PubMed ID: 28401876
    [Abstract] [Full Text] [Related]

  • 14. Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study.
    Asare K, Sookrajh Y, van der Molen J, Khubone T, Lewis L, Lessells RJ, Naidoo K, Sosibo P, van Heerden R, Garrett N, Dorward J.
    Lancet Glob Health; 2024 Feb 02; 12(2):e282-e291. PubMed ID: 38142692
    [Abstract] [Full Text] [Related]

  • 15. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
    Santevecchi BA, Miller S, Childs-Kean LM.
    Ann Pharmacother; 2020 Dec 02; 54(12):1252-1259. PubMed ID: 32517480
    [Abstract] [Full Text] [Related]

  • 16. Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.
    d'Arminio Monforte A, Tavelli A, Di Biagio A, Sarmati L, Marchetti GC, Bai F, Cingolani A, Quiros Roldan E, Mussini C, Lichtner M, Vergori A, Piconi S, Orofino G, Fusco FM, Bandera A, Nozza S, Castagna A, Antinori A, ICONA Foundation Study Group.
    J Antimicrob Chemother; 2024 Jun 03; 79(6):1279-1288. PubMed ID: 38581349
    [Abstract] [Full Text] [Related]

  • 17. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
    Girouard MP, Sax PE, Parker RA, Taiwo B, Freedberg KA, Gulick RM, Weinstein MC, Paltiel AD, Walensky RP.
    Clin Infect Dis; 2016 Mar 15; 62(6):784-91. PubMed ID: 26658053
    [Abstract] [Full Text] [Related]

  • 18. Efficacy, Convenience, Safety and Durability of DTG-Based Antiretroviral Therapies: Evidence from a Prospective Study by the Italian MaSTER Cohort.
    Fusco P, Nasta P, Quiros-Roldan E, Tondinelli A, Costa C, Fornabaio C, Mazzini N, Prosperi M, Torti C, Carosi G.
    Viruses; 2023 Apr 06; 15(4):. PubMed ID: 37112904
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study.
    Baldin G, Ciccullo A, Capetti A, Rusconi S, Sterrantino G, Cossu MV, Giacomelli A, Lagi F, Latini A, Bagella P, De Luca A, Di Giambenedetto S, Madeddu G.
    HIV Med; 2019 Feb 06; 20(2):164-168. PubMed ID: 30457197
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis.
    Lagi F, Botta A, Kiros ST, Meli M, Borchi B, Cavallo A, Pozzi M, Bartoloni A, Sterrantino G.
    Int J Antimicrob Agents; 2022 Jan 06; 59(1):106465. PubMed ID: 34699933
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.